Oncogenic action of phospholipase A2 in prostate cancer.
about
Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverriniPolyunsaturated fatty acid metabolism in prostate cancerSecretory phospholipase-A2 and fatty acid composition in oral reactive lesions: a cross-sectional studySecretory phospholipase A2 enzymes as pharmacological targets for treatment of diseaseSynthesis of oligo(ethylene glycol) substituted phosphatidylcholines: secretory PLA2-targeted precursors of NSAID prodrugsPeptidophospholipids: synthesis, phospholipase A2 catalyzed hydrolysis, and application to development of phospholipid prodrugs.Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients.Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1.Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathySecretory phospholipase A₂ responsive liposomes.Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanismsSynthesis of mixed-chain phosphatidylcholines including coumarin fluorophores for FRET-based kinetic studies of phospholipase A(2) enzymes.Cytosolic phospholipase A2 (cPLA2) IVA as a potential signature molecule in cigarette smoke condensate induced pathologies in alveolar epithelial lineages.Arachidonic acid stimulates cell adhesion through a novel p38 MAPK-RhoA signaling pathway that involves heat shock protein 27.Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.Do annexins participate in lipid messenger mediated intracellular signaling? A question revisited.Synthesis of lipids for development of multifunctional lipid-based drug-carriers.Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.Stage-specific expression, immunolocalization of Clonorchis sinensis lysophospholipase and its potential role in hepatic fibrosis.Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer.Haloenol pyranones and morpholinones as antineoplastic agents of prostate cancer.Tumor cell group via phospholipase A₂ is involved in prostate cancer development.High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner.Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer.The binding mode of petrosaspongiolide M to the human group IIA phospholipase A(2): exploring the role of covalent and noncovalent interactions in the inhibition process.Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner.Tissue fatty acid composition and secretory phospholipase-A2 activity in oral squamous cell carcinoma.
P2860
Q21266569-A2E70451-20B7-4597-808A-02794A26AC01Q24629893-2010866C-A2F0-4B96-BB10-C6E7B61C9053Q33612945-03EBF464-41F8-4B17-9C74-E9A0C02EB62CQ33923169-8197FBD5-46A0-4981-A79E-4DC1163073B2Q34081569-0EAB9EFE-E7F7-4FF3-8227-8C498BBF9713Q34282797-3D50CE39-265F-4E8B-BA61-A7EC95E6D532Q34339067-C7F07FA4-A9C9-4DA1-BF22-D71342BE9189Q34801388-9E978E5E-53E0-4D91-A685-001B1FBE25F8Q34941725-9B122918-052D-4120-A83D-E5EA861897FDQ35385515-F480C82E-7977-4ED1-9C45-02508D368812Q36485297-6D245250-0CD8-40F1-8CBA-2D1D807E7C7DQ37032274-09C6C9C5-5DF7-4635-9525-FE410DD3EFF7Q37178634-8A14E0A4-A46A-4900-9F23-27F83A46A5B2Q37344074-049A24AA-B51D-4608-9991-F5D46B3085DEQ37392792-4A1B4784-D376-47BC-BAE6-41966DEF5133Q37624230-38BE75FC-DEEC-41B0-AC2B-C93588BC3995Q38018345-9DB15B38-CA80-438F-8745-1816C7A108D5Q38733163-F7A58DCA-06DE-4007-9C04-5A1604D75500Q38975182-D59986B1-C7D7-4916-ABA7-9948FEA5F5DEQ39136980-40141193-74B4-44F4-B408-45914FF1A376Q39238185-547AE489-CF98-48AC-AE66-E92657693273Q39297921-43DA35D6-C073-4B54-A2D0-F86440BA044AQ39335230-BF6146DF-F3BA-48FE-BD58-0CCCB1482579Q39660426-F44C232E-451B-4190-854C-F67A0ED1169FQ41134388-E34EA15E-03CB-4D1C-BE71-2B1CAAA506A3Q41985042-9105754C-31D0-4F92-81C1-118882A204E4Q42045155-D6685589-F0A4-4247-AD3D-6B0947D22E5BQ43247211-179CA2DB-8713-4070-B4F3-F3D1E2C3958EQ46208929-AB50DA0A-8B04-4C73-986D-E11E7C60B1F6Q51316539-01A2B0C3-5403-45A8-8977-C80960B3A810Q53228838-A4DE99C7-7A06-4D2E-8072-59BFCFB55A22
P2860
Oncogenic action of phospholipase A2 in prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Oncogenic action of phospholipase A2 in prostate cancer.
@ast
Oncogenic action of phospholipase A2 in prostate cancer.
@en
type
label
Oncogenic action of phospholipase A2 in prostate cancer.
@ast
Oncogenic action of phospholipase A2 in prostate cancer.
@en
prefLabel
Oncogenic action of phospholipase A2 in prostate cancer.
@ast
Oncogenic action of phospholipase A2 in prostate cancer.
@en
P2093
P1433
P1476
Oncogenic action of phospholipase A2 in prostate cancer.
@en
P2093
Garry G Graham
Kieran F Scott
Manish Patel
Qihan Dong
P356
10.1016/J.CANLET.2005.08.012
P407
P577
2005-09-22T00:00:00Z